- Home
- REBN vs MYNZ Comparison
REBN vs MYNZ Comparison
Compare REBN & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REBN
- MYNZ
- Stock Information
- Founded
- REBN 2015
- MYNZ 2021
- Country
- REBN United States
- MYNZ Germany
- Employees
- REBN N/A
- MYNZ N/A
- Industry
- REBN Restaurants
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- REBN Consumer Discretionary
- MYNZ Health Care
- Exchange
- REBN Nasdaq
- MYNZ Nasdaq
- Market Cap
- REBN 9.4M
- MYNZ 7.9M
- IPO Year
- REBN 2022
- MYNZ 2021
- Fundamental
- Price
- REBN $1.97
- MYNZ $1.08
- Analyst Decision
- REBN
- MYNZ Strong Buy
- Analyst Count
- REBN 0
- MYNZ 1
- Target Price
- REBN N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- REBN 51.5K
- MYNZ 911.8K
- Earning Date
- REBN 11-19-2025
- MYNZ 12-29-2025
- Dividend Yield
- REBN N/A
- MYNZ N/A
- EPS Growth
- REBN N/A
- MYNZ N/A
- EPS
- REBN N/A
- MYNZ N/A
- Revenue
- REBN $6,663,303.00
- MYNZ $659,935.00
- Revenue This Year
- REBN $335.98
- MYNZ N/A
- Revenue Next Year
- REBN N/A
- MYNZ $5.03
- P/E Ratio
- REBN N/A
- MYNZ N/A
- Revenue Growth
- REBN 21.09
- MYNZ N/A
- 52 Week Low
- REBN $1.05
- MYNZ $0.92
- 52 Week High
- REBN $8.30
- MYNZ $10.56
- Technical
- Relative Strength Index (RSI)
- REBN 56.00
- MYNZ 38.50
- Support Level
- REBN $1.59
- MYNZ $1.00
- Resistance Level
- REBN $1.94
- MYNZ $2.09
- Average True Range (ATR)
- REBN 0.16
- MYNZ 0.21
- MACD
- REBN 0.05
- MYNZ -0.02
- Stochastic Oscillator
- REBN 81.82
- MYNZ 16.49
About REBN Reborn Coffee Inc.
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is an company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in one reportable segment, consisting of both the wholesale and retail sales of coffee, water, and other beverages.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.